Skip to main content

Clinical Trials Using Anti-CD7 CAR T Cells

Review the clinical trials studying anti-cd7 car t cells on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-4 of 4

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Status: Active
Location: 4 locations
Genetically Engineered Cells (Autologous Anti-CD7-CAR-CD28zeta T-cells) for the Treatment of Recurrent T-cell Malignancies
Status: Active
Location: 3 locations
Genetically Engineered Cells (BEAM-201) for the Treatment of Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Treating Patients with CD7+ Hematologic Cancers
Status: Temporarily Closed to Accrual
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri